Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.

Discover MannKind's evolving pipeline, strategic acquisitions, and upcoming Afrezza pediatric launch from the 2025 Wells Fargo Healthcare Conference.